Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Gets FDA Nod for New Kyprolis Combo Regimen for Multiple Myeloma

12/01/2021 | 02:34pm EST


ę MT Newswires 2021
All news about AMGEN INC.
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
PU
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
01/13Amgen, AstraZeneca's Asthma Drug Tezspire Available For Shipment to US Wholesalers
MT
01/13BridgeBio Pharma, Inc. Announces Clinical Collaboration with Amgen Inc. to Study BBP-39..
CI
01/13TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT..
PR
01/13Amgen and Astrazeneca Announces Tezspire™ Is Available for Shipment to Wholesalers..
CI
01/12AMGEN : Going Beyond Skin Deep When Managing Plaque Psoriasis
PU
01/11Amgen - EUROPEAN COMMISSION APPROVES LUMYKRAS (SOTORASIB) FOR PATIENTS WITH KRAS G12C-M..
AQ
01/11Amgen, Arrakis Start Research Project For RNA Degrader Treatments For Several Diseases;..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 019 M - -
Net income 2021 5 559 M - -
Net Debt 2021 21 986 M - -
P/E ratio 2021 23,2x
Yield 2021 2,96%
Capitalization 133 B 133 B -
EV / Sales 2021 5,94x
EV / Sales 2022 5,61x
Nbr of Employees 24 300
Free-Float -
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 235,36 $
Average target price 238,36 $
Spread / Average Target 1,28%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.4.62%132 570
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317